Familial hyperlipidemia type 1 (Homo sapiens)
From WikiPathways
Description
Familial hyperlipidemias are classified according to the Fredrickson classification. Type 1 of this classification is linked to a decrease of LPL, either through mutations on the gene itself or because of other factors. LPL hydrolyzed triglycerides in chylomicrons and in very low-density lipoproteins. Type 1 familial hyperlipidemia shows an increase of chylomicrons. LPL normally hydrolizes these chylomicrons into chylomicron remnants. However, mutations in LPL have been shown to be the cause of the first form of type 1 hyperlipidemia. APOC2 is an essential cofactor for LPL activation, which is stabalized by APOA5. Studies have found another form of LPL activity, but with an increased amount of LPL inhibitors. These inhibitors are ANGPTL3,4 and 8. Which of these are inhibiting LPL depends on the tissue the LPL is in.
Quality Tags
Ontology Terms
Bibliography
View all... |
- Feingold KR; ''Introduction to Lipids and Lipoproteins''; , 2000 PubMed Europe PMC Scholia
- Todur SP, Ashavaid TF; ''Association of CETP and LIPC Gene Polymorphisms with HDL and LDL Sub-fraction Levels in a Group of Indian Subjects: A Cross-Sectional Study.''; Indian J Clin Biochem, 2013 PubMed Europe PMC Scholia
- Liu M, Mei X, Herscovitz H, Atkinson D; ''N-terminal mutation of apoA-I and interaction with ABCA1 reveal mechanisms of nascent HDL biogenesis.''; J Lipid Res, 2019 PubMed Europe PMC Scholia
- Huang A, Sun D; ''Sexually Dimorphic Regulation of EET Synthesis and Metabolism: Roles of Estrogen.''; Front Pharmacol, 2018 PubMed Europe PMC Scholia
- Ayhan H, Gormus U, Isbir S, Yilmaz SG, Isbir T; ''SCARB1Gene Polymorphisms and HDL Subfractions in Coronary Artery Disease.''; In Vivo, 2017 PubMed Europe PMC Scholia
- Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE; ''Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.''; Diabetes, 2020 PubMed Europe PMC Scholia
- Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witztum JL; ''Targeting APOC3 in the familial chylomicronemia syndrome.''; N Engl J Med, 2014 PubMed Europe PMC Scholia
- Burnett JR, Hooper AJ, Hegele RA; ''Familial Lipoprotein Lipase Deficiency''; , 1993 PubMed Europe PMC Scholia
- Go GW, Mani A; ''Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis.''; Yale J Biol Med, 2012 PubMed Europe PMC Scholia
- Lucero D, Islam P, Freeman LA, Jin X, Pryor M, Tang J, Kruth HS, Remaley AT; ''Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid-phase endocytosis.''; Biochim Biophys Acta Mol Cell Biol Lipids, 2020 PubMed Europe PMC Scholia
- Rhainds D, Brissette L; ''The role of scavenger receptor class B type I (SR-BI) in lipid trafficking. defining the rules for lipid traders.''; Int J Biochem Cell Biol, 2004 PubMed Europe PMC Scholia
- Goldberg AS, Hegele RA; ''Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.''; Drug Des Devel Ther, 2012 PubMed Europe PMC Scholia
- Obinata H, Kuo A, Wada Y, Swendeman S, Liu CH, Blaho VA, Nagumo R, Satoh K, Izumi T, Hla T; ''Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice.''; J Lipid Res, 2019 PubMed Europe PMC Scholia
- Wolska A, Dunbar RL, Freeman LA, Ueda M, Amar MJ, Sviridov DO, Remaley AT; ''Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.''; Atherosclerosis, 2017 PubMed Europe PMC Scholia
- Tosheska Trajkovska K, Topuzovska S; ''High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol.''; Anatol J Cardiol, 2017 PubMed Europe PMC Scholia
- Boughanem H, Bandera-Merchán B, Hernández-Alonso P, Moreno-Morales N, Tinahones FJ, Lozano J, Morcillo S, Macias-Gonzalez M; ''Association between theAPOA2rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI.''; Biomedicines, 2020 PubMed Europe PMC Scholia
- Geller AS, Polisecki EY, Diffenderfer MR, Asztalos BF, Karathanasis SK, Hegele RA, Schaefer EJ; ''Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.''; J Lipid Res, 2018 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
View all... |
Name | Type | Database reference | Comment |
---|---|---|---|
ANGPTL3 | GeneProduct | ENSG00000132855 (Ensembl) | |
ANGPTL4 | GeneProduct | ENSG00000167772 (Ensembl) | |
ANGPTL8 | GeneProduct | ENSG00000130173 (Ensembl) | |
APOA1 | GeneProduct | ENSG00000118137 (Ensembl) | |
APOA2 | GeneProduct | ENSG00000158874 (Ensembl) | |
APOA4 | GeneProduct | ENSG00000110244 (Ensembl) | |
APOA5 | GeneProduct | ENSG00000110243 (Ensembl) | |
APOC2 | GeneProduct | ENSG00000234906 (Ensembl) | |
CETP | GeneProduct | ENSG00000087237 (Ensembl) | |
Cholesterol | Metabolite | CHEBI:16113 (ChEBI) | |
Chylomicron | Metabolite | Q423126 (Wikidata) | |
Chylomicron remnant | Metabolite | Q14890553 (Wikidata) | |
Familial GPIHBP1 deficiency | Q102293691 (Wikidata) | ||
Familial apolipoprotein C-II deficiency | Q55998523 (Wikidata) | ||
Familial chylomicronemia
due to inhibition of lipoprotein lipase activity | Q102293256 (Wikidata) | ||
Familial hyperlipidemia | Q18554145 (Wikidata) | ||
Familial lipase maturation factor 1 deficiency | Q102294643 (Wikidata) | ||
Familial lipoprotein lipase deficiency | Q2349695 (Wikidata) | ||
GPIHBP1 | GeneProduct | ENSG00000277494 (Ensembl) | |
HDL | Metabolite | CHEBI:47775 (ChEBI) | |
IDL | Metabolite | CHEBI:132933 (ChEBI) | |
LCAT | GeneProduct | ENSG00000213398 (Ensembl) | |
LDL | Metabolite | CHEBI:47774 (ChEBI) | |
LDLR | GeneProduct | ENSG00000130164 (Ensembl) | |
LIPC | GeneProduct | ENSG00000166035 (Ensembl) | |
LMF1 | GeneProduct | ENSG00000103227 (Ensembl) | |
LPL | GeneProduct | ENSG00000175445 (Ensembl) | |
LRP1 | GeneProduct | ENSG00000123384 (Ensembl) | |
Lipoprotein | Metabolite | CHEBI:6495 (ChEBI) | |
PLTP | GeneProduct | ENSG00000100979 (Ensembl) | |
Phospholipid | Metabolite | CHEBI:16247 (ChEBI) | |
SEL1L | GeneProduct | ENSG00000071537 (Ensembl) | |
Triglyceride | Metabolite | CHEBI:17855 (ChEBI) | |
VLDL | Metabolite | CHEBI:39027 (ChEBI) |
Annotated Interactions
No annotated interactions